Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs
Some of the most anticipated Prospera study data to be shared include:
- Even when biopsy results are negative for rejection, elevated Prospera dd-cfDNA levels were strongly predictive of future adverse outcomes, including eGFR decline, DSA positivity, and graft loss. New data from the PEDAL study in 346 kidney transplant patients with non-rejection biopsy results showed that patients with positive Prospera results, which occurred in 18.2% of these cases, had significantly higher rates of adverse outcomes, including >6X the rate of graft loss. The data suggest that positive dd-cfDNA results indicate an increased risk for adverse outcomes, even when biopsy does not show rejection.
- Patients with persistently low Prospera dd-cfDNA levels had reliable and significantly lower adverse outcome rates, which may enable confident decisions to lower immunosuppression. In a new analysis of 989 kidney transplant recipients from the ProActive study, when a patient’s Prospera dd-cfDNA donor-fraction remained <0.5%, patients had significantly lower rates of adverse outcomes, including ~12X reduced odds of future rejection and ~5.5X reduced odds of future graft loss. These results demonstrate that low Prospera dd-cfDNA was prognostic of durable graft stability and reiterate the importance of ongoing and regular monitoring.
"Natera is leading the next phase of studies and evidence generation for dd-cfDNA,” said
Full list of Natera presentations at ATC :
Presenter:
The Edge of Detection: Defining Critical Thresholds for the Prospera Donor-Derived Cell-Free DNA Transplant Rejection Screen
Presenter:
Consistently Low Donor-Derived Cell-Free DNA Identifies Allograft Stability in Kidney Transplant Recipients
Presenter:
A Novel Hierarchical Machine Learning Framework for Predicting Kidney Transplant Rejection Subtype
Presenter:
Are Transplant APPs Ready for Certification? National Findings from the
Presenter:
Busting the Age Myth: Clinically Significant Genetic Findings in
Presenter: Keysha M. López
Genetic Testing in Kidney Transplant Candidates and Recipients: Three Cases of Adenine Phosphoribosyltransferase (APRT) Deficiency Identified in
Presenter:
Positive Genetic Test Results in Living Kidney Donor Candidates: Common and Broadly Distributed Across Genes
Presenter:
Carrier Findings Are Common and Clinically Relevant in Living Kidney Donor Candidates
Presenter:
In heart transplants, DSA-negative and DSA-positive antibody-mediated rejection have similar molecular features, timing, dd-cfDNA and leukocyte composition
Presenter:
Biopsy to Biomarker: Evolution of Post-Heart Transplant Surveillance Practices from the ProTECT Study
Presenter: Martina Mackova, Ph.D.
Comparing Histological Acute Cellular Rejection Grade 1R with Molecular Microscope® Diagnostic System Classifiers and Donor-Derived Cell-Free DNA (dd-cfDNA) Levels
Presenter:
Incremental Increase in Donor-Derived Cell-Free DNA (dd-cfDNA) and Risk of Molecular Rejection in Heart Transplant (HT) Recipients
Presenter:
Conversations That Lead to Action: Genetic Counselors and Living Kidney Donors
Presenter:
Donor-Derived Cell-Free DNA (dd-cfDNA) and Clinical Outcomes in Heart Transplant (HT) Patients (Pts) with Antibody Mediated Rejection (AMR): ProTECT Study
Presenter:
Association Between dd-cfDNA and
Presenter:
Dd-cfDNA in Kidney Transplant Recipients (KTRs) with Cancer
Presenter:
Torque Teno Virus (TTV) Viral Load (VL) Correlates with Tacrolimus (TAC) Levels but Not Lymphocyte Subsets or Immunoglobulins After Lung Transplantation (LT)
Presenter:
Donor-Derived Cell-Free DNA for Detection of Rejection After Pancreas Transplantation
Presenter: Martina Mackova, Ph.D.
In Heart Transplants Current Standard-of-Care Management of TCMR and ABMR is Often Associated with Persistence of Molecular Rejection and Elevated dd-cfDNA
Presenter:
Current Standard-of-Care Management of TCMR and ABMR in Kidney Transplant Patients is Associated with Persistence of Molecular Rejection and Elevated dd-cfDNA
Presenter:
Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR)
Presenter:
Post-Rejection Donor-Derived Cell-Free DNA and Serum Creatinine Trends in Kidney Transplant Recipients
Presenter: Suphamai Bunnapradist, M.D.
Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Biopsy-Negative Kidney-Transplant Recipients
About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260618969671/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
